Inspired by children with cancer, Day One Biopharmaceuticals creatively and intentionally develops promising new therapies that change the outcome for people of all ages living with cancer. Day One\'s first announced program is DAY101, an oral, once-a-week, type II pan-RAF inhibitor that is currently being evaluated in human clinical trials. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop emerging cancer treatments that can help both children and adults living with cancer. Through Day One and its collaborators, cancer drug development comes of age.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/21/20 | $60,000,000 | Series A |
Access Industries Atlas Venture Canaan Partners | undisclosed |
| 02/11/21 | $130,000,000 | Series B |
Access Biotechnology Atlas Venture Boxer Capital BVF Partners Canaan Partners Franklin Templeton Janus Henderson Investors Perceptive Advisors RA Capital Management  T. Rowe Price Associates Viking Global Investors | undisclosed |
